Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Assets Average of $800.5 million for Q1 2026, down 26.47% year-over-year from $1.1 billion in Q1 2025, and down 9.42% quarter-over-quarter from $883.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Assets Average (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Assets Average for 11 consecutive years, with $800.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 26.47% year-over-year to $800.5 million; the TTM figure through Mar 2026 stood at $800.5 million (down 26.47% YoY), while the FY2025 annual figure was $1.0 billion, down 18.41% from the prior year.
- Assets Average retreated to $800.5 million in Q1 2026 per NTLA's latest filing, from $883.7 million in the prior quarter.
- Across five years, Assets Average topped out at $1.5 billion in Q1 2023 and bottomed at $800.5 million in Q1 2026.
- Historically, Assets Average has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Assets Average soared 79.24% — and 2026, when it retreated 26.47%.
- Intellia Therapeutics' Assets Average stood at $1.3 billion in 2022, then fell by 2.31% to $1.3 billion in 2023, then dropped by 7.07% to $1.2 billion in 2024, then dropped by 25.25% to $883.7 million in 2025, then dropped by 9.42% to $800.5 million in 2026.
- Business Quant data shows NTLA's Assets Average at $800.5 million in Q1 2026, $883.7 million in Q4 2025, and $912.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 807.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 807.97 Mn |
| Mar 31, 2026 | 800.45 Mn |
| Dec 31, 2025 | 883.70 Mn |
| Sep 30, 2025 | 912.08 Mn |
| Jun 30, 2025 | 942.53 Mn |
| Mar 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 1.18 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 1.28 Bn |
| Dec 31, 2023 | 1.27 Bn |
| Sep 30, 2023 | 1.28 Bn |
| Jun 30, 2023 | 1.37 Bn |
| Mar 31, 2023 | 1.47 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 1.25 Bn |
| Dec 31, 2021 | 1.31 Bn |
| Sep 30, 2021 | 1.00 Bn |